Enzon Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Enzon Pharma signed a big deal, filing an 8-K on May 16th.

AI Summary

On May 16, 2024, Enzon Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing also notes material modifications to the rights of security holders and includes financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing indicates a significant event for Enzon Pharmaceuticals, potentially impacting its operations, financial standing, or shareholder rights.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or alter existing ones for a company.

Key Players & Entities

• Enzon Pharmaceuticals, Inc. (company) — Registrant
• May 16, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation

FAQ

Filing Documents

• tm2415024d1_8k.htm (8-K) — 29KB
• tm2415024d1_ex4-1.htm (EX-4.1) — 14KB
• 0001104659-24-064247.txt ( ) — 210KB
• enzn-20240516.xsd (EX-101.SCH) — 3KB
• enzn-20240516_lab.xml (EX-101.LAB) — 33KB
• enzn-20240516_pre.xml (EX-101.PRE) — 22KB
• tm2415024d1_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement. On May 16, 2024, Enzon Pharmaceuticals, Inc. (the " Company ") entered into the Second Amendment to the Section 382 Rights Agreement (the " Second Amendment "), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the " Rights Agreement "), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent. Effective June 2, 2021, the Company amended the Rights Agreement (the " First Amendment ") to extend the Final Expiration Date (as defined in the Rights Agreement) of the rights issued pursuant to the Rights Agreement from the close of business on August 13, 2021 to the close of business on June 2, 2024. The Second Amendment further extends the Final Expiration Date to the close of business on March 31, 2025. Except for the extension of the Final Expiration Date, the Rights Agreement otherwise remains unmodified. The Second Amendment has been adopted because the Company's management believes that it is in the best interests of the Company and its stockholders to extend the Final Expiration Date of June 2, 2024, as established in the First Amendment. The foregoing description does not purport to be complete and is qualified in its entirety by reference to the complete text of the Rights Agreement, which was filed with the U.S. Securities and Exchange Commission (the " SEC ") as Exhibit 4.1 to the Current Report on Form 8-K filed on August 14, 2020, the First Amendment, which was filed with the SEC as Exhibit 4.1 to the Current Report on Form 8-K filed on June 8, 2021, and the Second Amendment, a copy of which is attached as Exhibit 4.1 hereto and incorporated herein by reference.

03

Item 3.03 Material Modification to Rights of Security Holders. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 4.1 Second Amendment to the Section 382 Rights Agreement, dated as of May 16, 2024, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: May 22, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR